To address whether Nivolumab may affect the immune perturbations observed in metastatic melanoma patients, we compared the frequency of CD4+CD26+ T cells at W0 with those obtained after 12 weeks (W1) of treatment in a sub-cohort of 33 patients (Fig. 2A–C). Here, CD4 is linked to metastatic melanoma.